| Literature DB >> 28303109 |
Annamaria M Strangio1, Lucio Rinaldi1, Gianluigi Monniello2, Leuconoe Grazia Sisti3, Chiara de Waure3, Luigi Janiri1.
Abstract
OBJECTIVES: The first aim of our study was to compare the characteristics and comorbidities of patients with eating disorders between those who suffered from a childhood abuse and those who did not. Our second aim was to analyze the differences in the outcome of the psychodynamic therapy between abused and not abused patients.Entities:
Keywords: abuse; addiction disorder; adolescents; feeding and eating disorders; impulse control disorder; psychodynamic therapy
Year: 2017 PMID: 28303109 PMCID: PMC5332355 DOI: 10.3389/fpsyt.2017.00031
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Patients’ demographic and clinical characteristics.
| Total sample (26) | Abused patients (11) | Not abused patients (15) | ||
|---|---|---|---|---|
| M | 10 (38.5%) | 4 (36.4%) | 6 (40%) | 1 |
| F | 16 (61.5%) | 7 (63.6%) | 9 (60%) | |
| median | 16 | 16 | 16 | 0.458 |
| interquartile range (IQR) | 3 | 3 | 4 | |
| Anorexia | 5 (19.2%) | 1 (9.1%) | 4 (26.7%) | 0.629 |
| Binge eating disorder | 10 (38.5%) | 4 (364%) | 6 (40%) | |
| Bulimia | 2 (7.7%) | 1 (9.1%) | 1 (6.6%) | |
| Avoidant/restrictive food intake disorder | 9 (34.6%) | 5 (45.5%) | 4 (26.7%) | |
| Kleptomania | 1 (3.8%) | 1 (9.1%) | 0 | 0.346 |
| Conduct disorder | 13 (50%) | 6 (54.5%) | 7 (46.6%) | |
| Intermittent explosive disorder | 3 (11.5%) | 2 (18.2%) | 1 (6.7%) | |
| Oppositional defiant disorder | 2 (7.7%) | 1 (9.1%) | 1 (6.7%) | |
| None | 7 (26.9%) | 1 (9.1%) | 6 (40%) | |
| Substance abuse/dependence | 6 (23.1%) | 5 (45.4%) | 1 (6.7%) | 0.057 |
| Gambling | 1 (3.8%) | 1 (9.1%) | 0 | |
| Internet gambling | 7 (26.9%) | 2 (18.2%) | 5 (33.3%) | |
| None | 12 (46.2%) | 3 (27.3%) | 9 (60%) | |
| Avoidant | 5 (19.2%) | 2 (18.2%) | 3 (20%) | 1 |
| Dependent | 2 (7.7%) | 0 | 2 (13.3%) | 0.492 |
| Obsessive–compulsive | 4 (15.4%) | 1 (9.1%) | 3 (20%) | 0.614 |
| Passive–aggressive | 11 (42.3%) | 7 (63.6%) | 4 (26.7%) | 0.109 |
| Depressive | 6 (23.1%) | 3 (27.3%) | 3 (20%) | 1 |
| Paranoid | 8 (30.8%) | 5 (45.5%) | 3 (20%) | 0.218 |
| Schizotypal | 3 (11.5%) | 1 (9.1%) | 2 (13.3%) | 1 |
| Schizoid | 0 | 0 | 0 | – |
| Histrionic | 0 | 0 | 0 | – |
| Narcissistic | 2 (7.7%) | 2 (18.2%) | 0 | 0.169 |
| Borderline | 5 (19.2%) | 4 (36.4%) | 1 (6.7%) | 0.128 |
| Antisocial | 2 (7.7%) | 2 (18.2%) | 0 | 0.169 |
Baseline test values.
| Symptom variables | Abused patients | Not abused patients | |||
|---|---|---|---|---|---|
| Median | IQR | Median | IQR | ||
| SOM | 1.50 | 1.41 | 1 | 1.50 | 0.405 |
| OC | 2 | 1.7 | 1.3 | 2 | 0.550 |
| IS | 1.78 | 2.33 | 0.56 | 2 | 0.287 |
| DEP | 1.69 | 1.92 | 1.08 | 1.46 | 0.311 |
| ANX | 1.2 | 2 | 0.80 | 2.2 | 0.405 |
| HOS | 1.33 | 1 | 0.50 | 0.99 | |
| PHOB | 0.57 | 0.85 | 0.57 | 1.14 | 0.465 |
| PAR | 1.68 | 2.66 | 0.83 | 1.17 | 0.349 |
| PSY | 0.80 | 1.8 | 0.40 | 1.2 | 0.076 |
| GSI | 1.41 | 1.75 | 0.84 | 1.41 | 0.233 |
| SLEEP | 1.57 | 1.43 | 0.71 | 2 | 0.132 |
| DT | 1.29 | 2 | 1.71 | 3 | 0.897 |
| B | 0.63 | 2.62 | 0.87 | 1.38 | 0.917 |
| BD | 2.60 | 1.7 | 1.7 | 2.8 | 0.107 |
| PA | 2 | 1.14 | 1 | 2.01 | 0.177 |
| LSE | 2.16 | 2 | 1.66 | 2 | 0.274 |
| II | 2.14 | 1.57 | 1.71 | 1.86 | 0.499 |
| IA | 2.14 | 1.43 | 1.28 | 1.86 | 0.146 |
| ID | 1.63 | 2 | 1.63 | 2 | 0.979 |
| ED | 1.75 | 1 | 1.25 | 1 | |
| P | 1.33 | 2 | 1.16 | 1 | 0.639 |
| A | 0.86 | 1.29 | 1.42 | 1.57 | 0.585 |
| MF | 1.50 | 1.88 | 2 | 1.25 | 0.168 |
| A | 12 | 4 | 11 | 4 | 0.228 |
| IC | 6 | 2 | 5 | 4 | 0.289 |
| M | 18 | 6 | 11 | 4 | |
| P | 7 | 4 | 6 | 3 | 0.198 |
| SC | 18 | 4 | 14 | 5 | |
| CC | 15 | 3 | 11 | 4 | |
| IA | 19 | 4 | 17 | 7 | 0.201 |
| IM | 24 | 7 | 17 | 3 | |
| Inon Plan | 33 | 5 | 24 | 4 | |
| Tot Bis11 | 74 | 12 | 58 | 10 | |
| 12.5 | 33.58 | 10.71 | 17.93 | 0.392 | |
| 50 | 10 | 51 | 11 | 0.087 | |
SCL-90, symptom Checklist-90; SOM, somatization; Obs, obsessive–compulsive; IS, interpersonal sensitivity; DEP, depression; ANX, anxiety; HOS, hostility; PHOB, phobic anxiety; PAR, paranoid ideation; PSY, psychoticism; SLEEP, sleep disorders; GSI, Global Severity Index; EDI-3, Eating Disorders Inventory-3; DT, drive for thinness; B, bulimia; BD, body dissatisfaction; LSE, low self-esteem; PA, personal alienation; II, interpersonal insecurity; IA, interpersonal alienation; ID, interoceptive deficits; ED, emotional dysregulation; P, perfectionism; A, asceticism; MF, maturity fears; DES, Dissociative Experiences Scale; BIS-11, Barratt Impulsiveness Scale-11; A, attention; IC, cognitive instability; IM, Motor (M); P, perseverance; SF, self control; CC, cognitive complexity; A, attentional, IM, InonPlan, non-planning; GAF, global assessment of functioning.
Bold font indicates the test abbreviations and significant results.
Figure 1Variables from baseline to follow-up in the whole sample.
Results from statistical tests.
| Test | Baseline | 12 months | Test statistics | ||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | ||||
| SOM | 1 | 1.31 | 0.63 | 0.9 | −2.78 | −0.39 | |
| OC | 1.55 | 1.80 | 0.95 | 1.6 | −2.09 | −0.29 | |
| IS | 1.06 | 2.06 | 0.73 | 1.69 | −1.62 | 0.106 | −0.23 |
| DEP | 1.16 | 1.77 | 0.89 | 1.83 | −1.20 | 0.230 | −0.17 |
| ANX | 1.15 | 2.20 | 0.55 | 1.4 | −2.35 | −0.33 | |
| HOS | 1 | 1.71 | 0.33 | 2 | −1.46 | 0.144 | −0.20 |
| PHOB | 0.57 | 1 | 0.14 | 0.78 | −2.81 | < | −0.39 |
| PAR | 1 | 2.04 | 0.60 | 1.99 | −2.72 | 0.204 | −0.38 |
| PSY | 0.50 | 1.30 | 0.25 | 1.1 | −2.76 | −0.38 | |
| GSI | 0.98 | 1.46 | 0.48 | 1.34 | −2.35 | −0.33 | |
| SLEEP | 1.07 | 1.75 | 0.86 | 1.43 | −2.09 | −0.29 | |
| DT | 1.57 | 2 | 1.14 | 1.74 | −1.83 | 0.067 | −0.25 |
| B | 0.75 | 1.41 | 0.50 | 1.13 | −0.72 | 0.475 | −0.10 |
| BD | 2 | 2.1 | 1.57 | 2.2 | −1.72 | 0.085 | −0.24 |
| PA | 1.28 | 1.75 | 1.35 | 1.31 | −0.17 | 0.869 | −0.02 |
| LSE | 1.83 | 2 | 1.42 | 1 | −1.67 | 0.094 | −0.23 |
| II | 1.78 | 1.64 | 1.64 | 1.18 | −1.24 | 0.216 | −0.17 |
| IA | 1.57 | 1.61 | 1.38 | 0.71 | −0.30 | 0.764 | −0.04 |
| ID | 1.63 | 2 | 1.06 | 1.45 | −1.98 | −0.28 | |
| ED | 1.44 | 1 | 0.99 | 1.16 | −2.13 | −0.30 | |
| P | 1.25 | 1 | 1.33 | 1 | −0.03 | 0.976 | −0.0 |
| A | 1.28 | 1.32 | 0.98 | 1.10 | −2.04 | −0.28 | |
| MF | 1.75 | 1.50 | 1.37 | 0.65 | −1.34 | 0.181 | −0.19 |
| A | 11.50 | 4 | 11.50 | 4 | −0.21 | 0.834 | −0.03 |
| IC | 6 | 3 | 5 | 2 | −2.40 | −0.33 | |
| M | 12.50 | 8 | 13.50 | 13 | −0.32 | 0.746 | −0.04 |
| P | 7 | 3 | 7 | 2 | −0.16 | 0.870 | −0.02 |
| SC | 15 | 8 | 13.50 | 14 | −0.38 | 0.704 | −0.05 |
| CC | 12 | 4 | 13 | 11 | −0.29 | 0.771 | −0.04 |
| IA | 18 | 5 | 15.50 | 6 | −1.78 | 0.075 | −0.25 |
| IM | 18.50 | 7 | 20 | 6 | −0.87 | 0.385 | −0.12 |
| Inon Plan | 26.50 | 9 | 27 | 10 | −0.34 | 0.731 | −0.05 |
| Tot Bis11 | 65.50 | 15 | 63.50 | 13 | −0.73 | 0.465 | −0.10 |
| DES | 11.61 | 23.66 | 7.22 | 15.2 | − | −0.36 | |
| 51 | 19 | 61 | 10 | − | −0.55 | ||
No significant changes were found ion SCID II items.
Stratified analysis.
| Test | Baseline | 12 months | Test statistics | ||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | ||||
| SOM | 1 | 1.50 | 0.53 | 1 | −2.90 | −0.53 | |
| OC | 1.3 | 2 | 0.80 | 1.1 | −2.05 | −0.37 | |
| IS | 0.56 | 2 | 0.50 | 1 | −1.36 | 0.173 | −0.25 |
| DEP | 1.08 | 1.46 | 0.46 | 1.34 | −1.50 | 0.133 | −0.27 |
| ANX | 0.80 | 2.2 | 0.40 | 0.9 | −1.61 | 0.107 | −0.29 |
| HOS | 0.50 | 0.99 | 0.20 | 1 | −1.57 | 0.117 | −0.29 |
| PHOB | 0.57 | 1.14 | 0 | 0.32 | −2.20 | −0.40 | |
| PAR | 0.83 | 1.17 | 0.44 | 1.40 | −1.34 | 0.182 | −0.24 |
| PSY | 0.40 | 1.2 | 0.20 | 0.4 | −1.45 | 0.142 | −0.26 |
| GSI | 0.84 | 1.41 | 0.40 | 0.72 | −2.10 | −0.38 | |
| SLEEP | 0.71 | 2 | 0.76 | 0.81 | −1.39 | 0.164 | −0.25 |
| DT | 1.71 | 3 | 0.86 | 1.67 | −1.48 | 0.140 | −0.27 |
| B | 0.87 | 1.38 | 0.34 | 1.11 | −0.98 | 0.328 | −0.18 |
| BD | 1.7 | 2.8 | 0.87 | 2.1 | −1.37 | 0.172 | −0.25 |
| PA | 1 | 2.01 | 1.54 | 1.10 | −0.51 | 0.609 | −0.09 |
| LSE | 1.66 | 2 | 1.30 | 1 | −0.51 | 0.615 | −0.09 |
| II | 1.71 | 1.86 | 1.71 | 0.90 | −0.82 | 0.410 | −0.15 |
| IA | 1.28 | 1.86 | 1.42 | 0.57 | −1.04 | 0.300 | −0.19 |
| ID | 1.63 | 2 | 0.88 | 1.42 | −1.99 | −0.36 | |
| ED | 1.25 | 1 | 0.70 | 0.75 | −1.50 | 0.132 | −0.27 |
| P | 1.16 | 1 | 1.33 | 1 | −0.04 | 0.972 | −0.01 |
| A | 1.42 | 1.57 | 1 | 1.09 | −1.76 | 0.078 | −0.32 |
| MF | 2 | 1.25 | 1.4 | 1.70 | −1.33 | 0.184 | −0.24 |
| A | 11 | 4 | 11 | 4 | −0.07 | 0.944 | −0.01 |
| IC | 5 | 4 | 5 | 2 | −1.21 | 0.227 | −0.22 |
| M | 11 | 4 | 13 | 5 | −1.48 | 0.138 | −0.27 |
| P | 6 | 3 | 6 | 1 | −0.04 | 0.972 | −0.01 |
| SF | 14 | 5 | 12 | 2 | −0.28 | 0.776 | −0.05 |
| CC | 11 | 4 | 12 | 6 | −1.03 | 0.304 | −0.19 |
| IA | 17 | 7 | 15 | 7 | −0.60 | 0.550 | −0.11 |
| IM | 17 | 3 | 18 | 4 | −1.80 | 0.072 | −0.33 |
| Inon Plan | 24 | 4 | 24 | 6 | −0.50 | 0.614 | −0.09 |
| Tot Bis11 | 58 | 10 | 58 | 8 | −0.19 | 0.850 | −0.03 |
| 10.71 | 17.93 | 5.71 | 6.4 | −2.50 | −0.46 | ||
| 51 | 11 | 61 | 9 | −3.09 | −0.56 | ||
| SCL-90 | |||||||
| SOM | 1.50 | 1.41 | 1.02 | 1.1 | −0.71 | 0.48 | −0.15 |
| OC | 2 | 1.7 | 1.90 | 1.7 | −0.58 | 0.56 | −0.12 |
| IS | 1.78 | 2.33 | 1 | 2.45 | −0.85 | 0.40 | −0.18 |
| DEP | 1.69 | 1.92 | 1.2 | 1.92 | −0.27 | 0.79 | −0.06 |
| ANX | 1.2 | 2 | 0.90 | 1.4 | −1.75 | 0.08 | −0.37 |
| HOS | 1.33 | 1 | 1.67 | 2 | −0.47 | 0.64 | −0.10 |
| PHOB | 0.57 | 2.42 | 0.42 | 0.71 | −1.87 | 0.06 | −0.40 |
| PAR | 1.68 | 2.66 | 1.54 | 2.50 | −0.42 | 0.68 | −0.09 |
| PSY | 0.80 | 1.8 | 0.70 | 1.6 | −2.25 | −0.48 | |
| GSI | 1.41 | 1.75 | 1.19 | 1.63 | −1.16 | 0.25 | −0.25 |
| SLEEP | 1.57 | 1.43 | 171 | 1.29 | −1.72 | 0.09 | −0.37 |
| DT | 1.29 | 2 | 1.14 | 2.43 | −0.97 | 0.33 | −0.21 |
| B | 0.63 | 2.62 | 1 | 1 | −0.9 | 0.93 | −0.19 |
| BD | 2.60 | 1.7 | 1.7 | 2.9 | −1.28 | 0.20 | −0.27 |
| PA | 2 | 1.14 | 1.28 | 1.66 | −1.02 | 0.31 | −0.22 |
| LSE | 2.16 | 2 | 2 | 1 | −1.82 | 0.07 | −0.39 |
| II | 2.14 | 1.57 | 1.14 | 1.42 | −0.66 | 0.51 | −0.14 |
| IA | 2.14 | 1.43 | 1.28 | 0.71 | −1.48 | 0.14 | −0.31 |
| ID | 1.51 | 2 | 1.12 | 1.63 | −0.61 | 0.54 | −0.13 |
| ED | 1.75 | 1 | 1.35 | 1.88 | −1.60 | 0.11 | −0.34 |
| P | 1.33 | 2 | 1 | 1 | −0.15 | 0.88 | −0.03 |
| A | 0.86 | 1.29 | 0.96 | 1.72 | −1.36 | 0.17 | −0.29 |
| MF | 1.50 | 1.88 | 1.25 | 0.32 | −0.46 | 0.65 | −0.10 |
| A | 12 | 4 | 13 | 3 | −0.14 | 0.88 | −0.03 |
| IC | 6 | 2 | 4 | 2 | −1.90 | 0.06 | −0.40 |
| M | 18 | 6 | 15 | 6 | −1.21 | 0.23 | −0.26 |
| P | 7 | 4 | 8 | 3 | −0.43 | 0.67 | −0.09 |
| SF | 18 | 4 | 19 | 5 | −0.27 | 0.79 | −0.06 |
| CC | 15 | 3 | 14 | 8 | −0.51 | 0.61 | −0.11 |
| IA | 19 | 4 | 17 | 4 | −1.89 | 0.06 | −0.40 |
| IM | 24 | 7 | 23 | 5 | −0.81 | 0.42 | −0.17 |
| Inon Plan | 33 | 5 | 33 | 3 | −0.05 | 0.96 | −0.01 |
| Tot Bis11 | 74 | 12 | 70 | 10 | −1.36 | 0.17 | −0.29 |
| 12.5 | 33.58 | 13.57 | 21.8 | −1.29 | 0.20 | −0.27 | |
| 50 | 10 | 61 | 29 | −2.53 | −0.54 | ||
Bold font indicates the test abbreviations and significant results.
Figure 2Stratified analysis variables baseline to follow-up. Abused/non-abused (p < 0.05).